Artificial Heart Valves: Engineering a Fix for the Bodys Pump

A Valve Opens and Closes 100,000 Times a Day

The human heart contains four valves—mitral, aortic, tricuspid, and pulmonary—that open and close with each heartbeat to keep blood flowing in one direction. Over a 75-year lifespan, each valve cycles more than 2.7 billion times. When disease narrows a valve (stenosis) or allows it to leak backward (regurgitation), the heart compensates by working harder. Eventually, it fails. Valve disease affects roughly 2.5% of the global population, and severe cases require surgical replacement.

The first successful artificial heart valve implantation was performed by Charles Hufnagel in 1952, using a caged-ball design placed in the descending aorta. The device was crude by modern standards, but it proved the concept. Since then, more than 300,000 valve replacements are performed worldwide each year, using two broad categories: mechanical valves and bioprosthetic valves.

Mechanical Valves: Durability at a Cost

Mechanical valves are made entirely from synthetic materials—pyrolytic carbon, titanium, and polyester fabric. They last decades, often outliving the patient. Three main designs have been used historically.

The bileaflet design dominates the mechanical valve market today. Its hemodynamic profile closely mimics natural valve flow patterns. Pyrolytic carbon, the material of choice for leaflets, is exceptionally smooth, hard, and biocompatible—it produces minimal blood cell damage and resists thrombus formation better than metals.

The critical drawback is clotting. All mechanical valves require lifelong anticoagulation therapy, typically with warfarin. Patients must maintain a target INR (international normalized ratio) of 2.0 to 3.0 for aortic valves and 2.5 to 3.5 for mitral valves. Without anticoagulation, the risk of valve thrombosis or stroke rises sharply.

• Warfarin requires regular blood monitoring, typically every 2–4 weeks.
• Dietary interactions with vitamin K complicate dosing.
• Bleeding risk increases, particularly in older patients.
• Warfarin is teratogenic, limiting its use in women of childbearing age.

Bioprosthetic Valves: Tissue That Wears Out

Bioprosthetic valves use chemically treated animal tissue—most often bovine pericardium or porcine aortic valve leaflets—mounted on a stent frame. The tissue is fixed in glutaraldehyde, which cross-links collagen fibers to reduce immunogenicity and increase durability.

• Bioprosthetic valves do not require long-term anticoagulation, though short-term anticoagulation for 3–6 months post-surgery is common.
• They provide more natural hemodynamics and are quieter than mechanical valves (mechanical valves produce an audible click).
• Their main limitation is structural deterioration. Calcification and leaflet tears typically require re-operation after 10–20 years.
• Younger patients face a higher rate of bioprosthetic valve degeneration due to more active calcium metabolism and higher cardiac output.

Choosing Between Mechanical and Bioprosthetic

The choice depends on patient age, lifestyle, and risk tolerance. Current guidelines from the American Heart Association and the European Society of Cardiology generally recommend mechanical valves for patients under 50 and bioprosthetic valves for patients over 65, with shared decision-making for those in between. The trend over the past two decades has shifted strongly toward bioprosthetic valves, partly because transcatheter valve-in-valve procedures now allow a new bioprosthetic valve to be placed inside a failing one without open-heart surgery.

TAVR: Replacing a Valve Without Opening the Chest

Transcatheter aortic valve replacement (TAVR), also called TAVI, has transformed the treatment of aortic stenosis since its first human implantation by Alain Cribier in 2002. A bioprosthetic valve is crimped onto a catheter, threaded through the femoral artery to the heart, and expanded inside the diseased native valve.

The PARTNER 3 trial, published in 2019, demonstrated that TAVR was superior to surgery in low-risk patients at one year, accelerating adoption across all risk categories. By 2023, TAVR accounted for more than half of all aortic valve replacements in the United States.

Engineering Challenges That Remain

Valve engineering faces several unresolved problems.

• Paravalvular leak: TAVR valves sometimes fail to seal completely against the calcified native valve, allowing blood to leak around the prosthesis.
• Conduction disturbances: Up to 20% of TAVR patients require a permanent pacemaker because the expanded stent frame compresses the heart's electrical conduction pathways.
• Leaflet thrombosis: Subclinical clot formation on bioprosthetic leaflets, detectable by CT imaging, occurs in 10–15% of TAVR and surgical bioprosthetic valves. The clinical significance is still debated.
• Durability: TAVR valves have been implanted for only about 20 years, so true long-term durability data remain incomplete.

Research into tissue-engineered heart valves—grown from a patient's own cells on a biodegradable scaffold—promises a valve that can grow, repair, and remodel. Several teams have demonstrated proof of concept in animal models, but no tissue-engineered valve has reached routine clinical use as of 2025. The gap between laboratory success and a reliable, mass-producible living valve remains substantial.

This article is for informational purposes only. Consult a qualified professional.